scholarly journals Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

2019 ◽  
Vol 63 (12) ◽  
Author(s):  
Wayne Greaves ◽  
Hong Wan ◽  
Ka Lai Yee ◽  
Bhargava Kandala ◽  
Pavan Vaddady ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Tenofovir Disoproxil Fumarate ◽  
Phase 1 ◽  
Transcriptase Inhibitor ◽  
Phase 3 ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Shift Trial ◽  
Post Hoc ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

ABSTRACT Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.

scholarly journals Capravirine, a Nonnucleoside Reverse‐Transcriptase Inhibitor in Patients Infected with HIV‐1: A Phase 1 Study

2004 ◽  
Vol 190 (11) ◽  
pp. 1957-1961 ◽  
Author(s):  
Benjamin E. Gewurz ◽  
Mark Jacobs ◽  
Jo Ann Proper ◽  
Thomas A. Dahl ◽  
Tamio Fujiwara ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Phase 1 ◽  
Transcriptase Inhibitor ◽  
Phase 1 Study ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

scholarly journals Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

2020 ◽  
Vol 64 (11) ◽  
Author(s):  
Pavan Vaddady ◽  
Bhargava Kandala ◽  
Ka Lai Yee
Keyword(s):  
Transcriptase Inhibitor ◽  
Population Pharmacokinetic ◽  
People Living With Hiv ◽  
Shift Trial ◽  
Treatment Naïve ◽  
Post Hoc ◽  
Living With Hiv ◽  
Reverse Transcriptase Inhibitor ◽  
Parameter Values ◽  
Hiv 1

ABSTRACT Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.)

scholarly journals Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.

1996 ◽  
Vol 40 (11) ◽  
pp. 2664-2668 ◽  
Author(s):  
A M Been-Tiktak ◽  
I Williams ◽  
H M Vrehen ◽  
J Richens ◽  
D Aldam ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Transcriptase Inhibitor ◽  
Viral Loads ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Reverse Transcriptase Inhibitor ◽  
Cd4 Cell ◽  
Hiv 1

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor

Science ◽  
1990 ◽  
Vol 250 (4986) ◽  
pp. 1411-1413 ◽  
Author(s):  
V. Merluzzi ◽  
K. Hargrave ◽  
M Labadia ◽  
K Grozinger ◽  
M Skoog ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document